Fig. 4: Low doses of EZH2i synergize with ferroptosis inducers. | Cell Death & Disease

Fig. 4: Low doses of EZH2i synergize with ferroptosis inducers.

From: A targetable antioxidant defense mechanism to EZH2 inhibitors enhances tumor cell vulnerability to ferroptosis

Fig. 4: Low doses of EZH2i synergize with ferroptosis inducers.The alternative text for this image may have been generated using AI.

A, B ACC cells treated for 48 h with GSK126 (5 μM) alone or in combination with inhibitors for lipid metabolism enzymes: Orlistat (ORLI 100 μM), FASNi (G28UCM, 1 μM), ACLYi (SB204990, 50 μM), ATGLi (ATGLstatin, 50 μM), SCD1i (A959572, 5 nM), ACATi (Avasimibe, 2.5 μM), CD36i (Sulfosuccinimidyl oleate, 10 μM), and CPT1i (Etomoxir, 10 μM). C, D ACC cells treated for 48 h with GSK126 (5 μM) in the presence or absence of RSL3 (1 µM, for the last 4 h) and Ferrostatin (1 µM). (n = 3. Data were expressed as means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. ns not significant). E, F Confocal images of lipid peroxidation detected by BODIPY-C11 fluorescent dye in 2D (E) and 3D H295R cultures (F) (scale bar 50 µm). G Electron micrographs. Nucleus (N), nucleolus (n), mitochondria (black arrows), endoplasmic reticulum (black arrowheads), Golgi apparatus (G), electron transparent vesicles and vacuoles (v), lipid-like vacuoles of low electron density (*), lipid droplets (LD) (scale bars: 5 µm, 2 µm and 500 nm).

Back to article page